STEP 1 showed 14.9% body weight reduction at 2.4 mg weekly SELECT trial : Cardiovascular outcomes study showing 20% MACE reduction in patients with obesity and established CVD without diabetes FLOW trial : Kidney outcomes data demonstrating renal protective effects Oral formulation : Rybelsus provides an oral dosing option at 7-14 mg daily Real-world data : Millions of prescriptions written, providing extensive post-marketing safety surveillance Survodutide Research# Survodutide's evidence base is growing but not yet mature: Phase 2 obesity trial : Demonstrated dose-dependent weight loss up to approximately 19% body weight reduction, exceeding typical GLP-1 monotherapy results Phase 2 MASH data : Histological improvement in liver biopsies, including reduction in hepatic steatosis and inflammation scores Phase 3 programs : Active Phase 3 trials for both obesity and MASH, with results anticipated to define the compound's clinical profile Mechanism validation : Clinical data support the dual mechanism concept, with evidence of both appetite reduction and increased energy expenditure Limitation : No regulatory approvals
Though there were clinical studies consistent with our results [36], it has long been suggested that gradual weight loss is more beneficial for weight regain after treatment discontinuation [37]
touchREV Endocrinol 19(1):715
The comparison between compounded semaglutide and Ozempic is helpful because Ozempic is a proven, FDA-approved medication, while compounded medications are not evaluated for safety and effectiveness by the FDA, although they are useful during times of shortages or when a patient needs a personalized medication without a specific ingredient, for example
[10] It is used as an antidiabetic medication to treat type 2 diabetes [9] [12] [13] [14] and for weight loss
Both treatments involve injections, so patients should ensure injection-site reactions have resolved and inform practitioners about all medications
